Else Nutrition Holdings (TSE:BABY)
TSX:BABY
Top Page
Else Nutrition Holdings
(TSX:BABY)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.09
▼(-23.33% Downside)
Action:ReiteratedDate:01/16/26
The score is weighed down primarily by weak financial performance (revenue contraction, negative gross profit, continued losses, negative equity, and ongoing cash burn). Technical indicators are only modestly supportive (some short-term improvement but a weaker longer-term trend), while valuation is not compelling given the negative P/E and no dividend yield.
Positive Factors
Secular plant‑based demand
Else operates in a durable secular market: rising adoption of plant-based diets among parents expands the addressable market for infant and toddler nutrition. That tailwind supports longer-term revenue opportunity, partner interest, and strategic distribution expansion over months.
Negative Factors
Negative gross margin
Selling product below cost or carrying large write‑downs creates a structurally unsustainable unit economics profile. Persistently negative gross margins prevent internal funding of SG&A and R&D, and undermines any durable path to profitability without meaningful cost or pricing changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Secular plant‑based demand
Else operates in a durable secular market: rising adoption of plant-based diets among parents expands the addressable market for infant and toddler nutrition. That tailwind supports longer-term revenue opportunity, partner interest, and strategic distribution expansion over months.
Read all positive factors
Else Nutrition Holdings (BABY) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.24M
Dividend YieldN/A
Average Volume (3M)97.69K
Price to Earnings (P/E)―
Beta (1Y)0.30
Revenue Growth-25.08%
EPS Growth65.57%
CountryCA
Employees32
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-0.02
Shares Outstanding37,411,427
10 Day Avg. Volume142,494
30 Day Avg. Volume97,689
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.43
Price to Sales (P/S)0.32
P/FCF Ratio-0.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Else Nutrition Holdings Business Overview & Revenue Model
Company Description
Else Nutrition Holdings Inc. engages in the development, production, and sale of food and nutrition products for infants, toddlers, children, and adults in North America and Israel. It offers baby snacks; baby feeding accessories, such as feeding ...
How the Company Makes Money
Else Nutrition Holdings generates revenue primarily through the sale of its plant-based infant and toddler nutrition products. The company markets its products directly to consumers via its online platform and also through various retail partnersh...
Else Nutrition Holdings Earnings Call Summary
Earnings Call Date:Sep 16, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Mar 27, 2026
Earnings Call Sentiment Neutral
Else Nutrition has shown significant progress in reducing costs and improving operational efficiency, with promising advancements in regulatory pathways and international growth. However, challenges such as revenue decline, negative gross margin, and inventory constraints have impacted performance.Positive Updates
Expansion of Kids Ready-to-Drink Products
Else Nutrition's kids ready-to-drink products expanded to approximately 1,000 Walmart stores, showing significant market penetration and consumer interest.
Negative Updates
Revenue Decline
Total revenues for Q2 2025 were $1.5 million compared to $2.6 million in Q2 2024, mainly due to inventory constraints.
Read all updates
Q2-2025 Updates
Positive
Negative
Expansion of Kids Ready-to-Drink Products
Else Nutrition's kids ready-to-drink products expanded to approximately 1,000 Walmart stores, showing significant market penetration and consumer interest.
Read all positive updates
Company Guidance
During Else Nutrition's 2025 Second Quarter Conference Call, CEO Hamutal Yitzhak outlined several key metrics and strategic initiatives demonstrating the company's progress. The quarter saw total revenues of $1.5 million, a decrease from $2.6 million in Q2 2024, primarily due to inventory constraints and seasonal sales fluctuations. Gross profit faced a loss of $55,000, translating to a negative gross margin of -3.7%, affected by additional revenue reductions of CAD 270,000. Despite these challenges, operating expenses were significantly reduced by 60% year-over-year to $1.3 million, leading to a narrowed operating loss of $1.4 million, an improvement of 55% from the previous year. Else is targeting cash flow positivity by late 2026 or early 2027, focusing on supply chain optimization, regulatory advancements, and strategic partnerships to enhance growth and profitability.Else Nutrition Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
28
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.67M | 7.97M | 9.36M | 8.53M | 4.69M | 1.48M |
| Gross Profit | -2.16M | -5.64M | -85.00K | 1.31M | 743.00K | 498.00K |
| EBITDA | -9.41M | -14.78M | -15.17M | -17.12M | -1.23M | -23.91M |
| Net Income | -9.96M | -15.18M | -15.61M | -17.61M | -1.62M | -24.10M |
Balance Sheet | ||||||
| Total Assets | 4.39M | 7.56M | 16.07M | 26.16M | 32.92M | 29.32M |
| Cash, Cash Equivalents and Short-Term Investments | 72.00K | 103.00K | 4.92M | 15.38M | 24.28M | 24.71M |
| Total Debt | 924.00K | 874.00K | 5.53M | 3.37M | 941.00K | 228.00K |
| Total Liabilities | 5.76M | 5.80M | 9.35M | 10.57M | 6.15M | 18.11M |
| Stockholders Equity | -1.37M | 1.75M | 6.72M | 15.60M | 26.77M | 11.21M |
Cash Flow | ||||||
| Free Cash Flow | -1.55M | -9.12M | -18.31M | -21.07M | -16.05M | -9.82M |
| Operating Cash Flow | -1.55M | -9.06M | -18.31M | -20.91M | -15.76M | -9.59M |
| Investing Cash Flow | 624.00K | 2.71M | -1.13M | 170.00K | 1.14M | -3.93M |
| Financing Cash Flow | 1.50M | 3.73M | 7.44M | 11.69M | 16.85M | 32.45M |
Else Nutrition Holdings Technical Analysis
Negative
0.12
Price Trends
0.09
Negative
0.11
Negative
0.15
Negative
Market Momentum
>-0.01
Positive
38.02
Neutral
15.28
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BABY, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.09, and below the 200-day MA of 0.15, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.02 is Neutral, neither overbought nor oversold. The STOCH value of 15.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BABY.
Else Nutrition Holdings Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | C$1.42B | 22.55 | 12.97% | 2.67% | 11.25% | 58.21% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
48 Neutral | C$24.12M | -1.45 | -1208.82% | ― | 190.07% | -2.88% | |
48 Neutral | C$11.90M | 33.38 | ― | ― | 69.12% | 43.02% | |
48 Neutral | C$10.27M | -2.15 | -241.90% | ― | -49.04% | 15.66% | |
45 Neutral | C$206.61M | -174.75 | -92.94% | ― | 212.16% | -46.40% | |
44 Neutral | C$2.24M | -3.11 | 5435.74% | ― | -25.08% | 65.57% |
* Consumer Defensive Sector Average
TSE:BABY
Else Nutrition Holdings
0.06
-0.19
-76.00%
TSE:BU
Burcon Nutrascience
1.90
0.00
0.00%
TSE:JWEL
Jamieson Wellness Inc
34.45
5.72
19.92%
TSE:HBFG
Happy Belly Food Group
1.58
0.36
29.51%
TSE:NPRA
Nepra Foods
0.10
-0.02
-20.00%
TSE:PNGA
Pangea Natural Food, Inc.
0.36
0.14
63.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.